Start Date
September 30, 2018
Primary Completion Date
October 31, 2019
Study Completion Date
February 28, 2021
MCS110
-MCS110 is an IgG1/κ humanized monoclonal antibody directed against human macrophage colony stimulating factor
Doxorubicin
-Standard of care
Cyclophosphamide
-Standard of care
Paclitaxel
-Standard of care
Bone marrow aspirate
-Time of enrollment and at time of surgery
Peripheral blood samples
-Time of enrollment and at time of surgery
Tumor tissue
-Time of enrollment and at time of surgery
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Washington University School of Medicine
OTHER